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Background. Patient decision aids should help people make evidence-informed decisions aligned with their values.
There is limited guidance about how to achieve such alignment. Purpose. To describe the range of values clarification
methods available to patient decision aid developers, synthesize evidence regarding their relative merits, and foster
collection of evidence by offering researchers a proposed set of outcomes to report when evaluating the effects of val-
ues clarification methods. Data Sources. MEDLINE, EMBASE, PubMed, Web of Science, the Cochrane Library,
and CINAHL. Study Selection. We included articles that described randomized trials of 1 or more explicit values
clarification methods. From 30,648 records screened, we identified 33 articles describing trials of 43 values clarifica-
tion methods. Data Extraction. Two independent reviewers extracted details about each values clarification method
and its evaluation. Data Synthesis. Compared to control conditions or to implicit values clarification methods, expli-
cit values clarification methods decreased the frequency of values-incongruent choices (risk difference, –0.04; 95%
confidence interval [CI], –0.06 to –0.02; P \ 0.001) and decisional conflict (standardized mean difference, –0.20;
95% CI, –0.29 to –0.11; P \ 0.001). Multicriteria decision analysis led to more values-congruent decisions than
other values clarification methods (x2 = 9.25, P = 0.01). There were no differences between different values clarifi-
cation methods regarding decisional conflict (x2 = 6.08, P = 0.05). Limitations. Some meta-analyses had high het-
erogeneity. We grouped values clarification methods into broad categories. Conclusions. Current evidence suggests
patient decision aids should include an explicit values clarification method. Developers may wish to specifically con-
sider multicriteria decision analysis. Future evaluations of values clarification methods should report their effects on
decisional conflict, decisions made, values congruence, and decisional regret.
Highlights
 Current evidence suggests patient decision aids should include an explicit values clarification method.
 To support health decisions that align with values, patient decision aid developers may wish to specifically
consider multicriteria decision analysis.
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Introduction
Shared decision making is appropriate in many situations
and is particularly indicated in clinical situations where
the ‘‘best’’ option may differ between people, depending
on what matters to them.1–3 What is important to one
person might be different from what is important to oth-
ers, and determining what is important can be difficult
even with the appropriate information and evidence at
hand. The process of shared decision making therefore
aims to help people make health-related decisions that
are informed by high-quality, well-presented, and well-
understood evidence,4–8 aligned with what matters to the
person or people affected by the decision and acted
upon.9–12 It follows that the process of clarifying and
expressing values is an important aspect of shared deci-
sion making and thus of patient decision aids. Within
patient decision aids, this process is supported by explicit
values clarification methods.
Explicit values clarification methods require users to
interact with something such as a worksheet or an inter-
active website to clarify what matters to them relevant to
a health decision. Such methods have been shown to
encourage desirable outcomes such as better alignment
with patients’ values13,14 and reduced decisional regret,
the latter particularly among people with lower health
literacy.15 However, explicit values clarification methods
are extremely diverse,16 and there has been little gui-
dance regarding their comparative effects on users’ deci-
sion making processes or outcomes,17 making it difficult
for patient decision aid developers to know which expli-
cit method to use. Patient decision aid developers might
look toward the preference elicitation literature for gui-
dance, but the guidance available18 is often tailored
toward aggregate-level decision making, such as regula-
tory decisions19 or health technology assessment,20 not
for supporting individual-level decision making.
This updated review sought to build upon previous ver-
sions of the International Patient Decision Aids Standards’
chapter on values clarification21,22 as well as previous evi-
dence syntheses that have established the advantages of
explicit values clarification methods over implicit methods
or no values clarification.13,14 We sought to advance the
science and practice of values clarification methods in 3
ways. First, we aimed to offer clear definitions and an
annotated summary of existing approaches that have been
or could be used as values clarification methods. Second,
we aimed to synthesize evidence of different techniques’
effects on health decision outcomes. Third, we aimed to
foster future evidence by offering researchers a proposed
set of outcomes to consider when evaluating the effects of
values clarification methods.
Definitions
Part of the challenge in studying or using values clarifica-
tion methods is that definitions vary and terms like
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values are used imprecisely in the patient decision sup-
port literature.23,24 Another challenge is that there is sub-
stantial overlap between values clarification methods
used in patient decision support and preference elicita-
tion methods used in health economics. To bring clarity
to this imprecision and overlap, we adopt working defi-
nitions in Table 1 for use in this article.
As noted above, we continue to use the term values
clarification even though this is sometimes misinterpreted
as implying a narrow definition of values. Changing
terms makes it difficult for people who are new to a field
to connect the dots across decades of previous research.
It is clear that previous research in values clarification
addressed issues that were broader than valuation of
treatment-specific attributes.21 In this update, we there-
fore move forward with the older terms, now with more
clarity about what they mean in our presentation of the
evidence.
Theoretical Rationale
Our interdisciplinary team determined that the theoreti-
cal rationale for values clarification required only a small
edit, shown in square brackets, to reflect the focus on
explicit methods. Like Fagerlin et al.,22 we assert the the-
oretical rationale for explicit values clarification methods
as being that they ‘‘should aim to [explicitly] facilitate at
least one or more of the following six decision making
Table 1 Definitions of Terms
Term Definition Adopted in This Article
Values An umbrella term referring to what matters to an individual relevant to a health
decision. Values may be directly relevant to decisions (e.g., ‘‘beliefs, feelings, or
perceptions regarding attributes of a treatment option’’) or indirectly relevant (e.g.,
goals; worldviews; family, religious, or cultural values).25 Values may be represented
qualitatively or, in some cases, quantitatively. This definition is deliberately broad.
Values clarification ‘‘The process of sorting out what matters to an individual relevant to a given health
decision.’’16 This definition emphasizes that what matters to an individual may be
broader than attribute-specific values. What matters may also include preferences,
concerns (e.g., concerns about changes in health status), and issues to do with the
context of a person’s life within which they would need to implement a decision (e.g.,
fitting a treatment plan into one’s work schedule).16
Values clarification methods ‘‘Strategies that are intended to help patients evaluate the desirability of options or
attributes of options within a specific decision context, in order to identify which
option [they] prefer.’’22
Implicit values clarification methods Strategies for facilitating values clarification that do not require people to interact with
anything or anyone—for example, describing ‘‘options in enough detail that clients
can imagine what it is like to experience the physical, emotional, and social
effects,’’14 or simply encouraging people to think about what matters to them.
Explicit values clarification methods Strategies for facilitating values clarification that require people to interact with
something or someone (e.g., filling out a worksheet, using an interactive website,
having a semistructured conversation with another person with the explicit purpose
of clarifying values, or engaging in another structured exercise).
Preferences The extent to which a decision option or health state is desirable or acceptable, either
in the abstract or in comparison to other options or health states. Preferences may be
represented qualitatively or, more commonly, quantitatively.26
Preference elicitation methods Processes by which preferences are drawn out.16 Preference elicitation methods may
vary according to the theory informing them. They are highly related to values
clarification methods. Although older terms revealed and stated preference elicitation
methods are no longer recommended, readers who encounter these terms in previous
preference elicitation literature should note that these may overlap with implicit and
explicit values clarification methods, respectively.
Tradeoffs When multiple desirable outcomes cannot all be achieved, one must forgo (or trade
off) some potential benefits or options to avail oneself of others. When users are
explicitly required to engage with tradeoffs, this means they must consider and
indicate what they are willing to give up to get something else or, in other words,
which potential harms are acceptable in exchange for their associated potential
benefits.16 For example, a user might indicate in a ranking exercise that they would
prioritize greater comfort at the end of life over additional months of life.
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processes: 1) Identifying options, which can include
either the narrowing down of options, or the generation
of options that were not offered at the outset, 2) Identi-
fying attributes of the situation and/or the options which
ultimately affect the patient’s preference in a specific
decision context, 3) Reasoning about options or attri-
butes of options, 4) Integrating attributes of options
using either compensatory or both compensatory and
noncompensatory decision rules, 5) Making holistic
comparisons, and 6) Helping decision makers retrieve
relevant values from long-term memory.’’ Pieterse et al.27
provided theory-based recommendations on processes
that values clarification methods could aim to facilitate.
Although reasoning is one of the potential processes
supported by values clarification, neither the definition
nor the theoretical rationale of values clarification meth-
ods requires that people who are being supported in
making a personal health decision must rationally delib-
erate about each option, or that the goal must always be
a fully rational choice. In some decision making situa-
tions, rational deliberation and rational choice may be
desired, while in others, they may not.28,29
Explicit Values Clarification Methods
Table 2 organizes strategies that can be used as explicit
values clarification methods in patient decision aids,
building upon previously developed lists of types of val-
ues clarification methods3,16 and reviews of preference
elicitation methods.30,31 Methods range from highly
structured strategies that can also be used for preference
elicitation in the context of health policy decision making
to substantially less structured strategies. While not every
use of a given method will be exactly the same, we
deemed them functionally similar in terms of how they
might be used and what the user experience might be in
a patient decision aid. Patient decision aids may use mul-
tiple strategies. For example, a user may be asked to use
a rating scale or visual analog scale whose values are
then used in a decision-analytic model.
Methods
Our overall methods were guided by the Cochrane hand-
book. We report according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)45
guidelines.
Eligibility Criteria
We included published reports of comparative evalua-
tions of explicit values clarification methods, whether
they were called ‘‘values clarification methods’’ in the
publications or not. This meant that we included trials of
preference elicitation methods that had been trialed as
values clarification methods (e.g., multicriteria decision
analysis or discrete-choice experiments). We included
evaluations using comparative methods (i.e., randomized
controlled trials or randomized experiments of 1 or more
values clarification methods). The comparisons could be
1 or more values clarification methods compared to a
control method or compared to each other. Because we
sought to understand the effects of values clarification
methods, we excluded evaluations using descriptive study
designs (e.g., acceptability and feasibility study, develop-
ment study), observational study designs (e.g., reporting
outcomes before and after use of a values clarification
method), and reports of values clarification methods that
did not evaluate the method independently of the patient
decision aid in which it was used. Randomized experi-
ments comparing 1 or more values clarification methods
had to use distinctly different methods, meaning that
more than the content or presentation of information in
the values clarification method varied.
We did not apply language restrictions. We applied
date restrictions to the portion of the review for which
we had already conducted a systematic review (i.e., eva-
luations of values clarification methods that used the
term values clarification).17,22 Specifically, for this sub-
group, we added articles indexed or published starting in
2014 to the existing set of articles indexed or published
prior to 2014 that we had already identified using the
same search strategy. We applied no date restrictions to
the new, expanded portion of the review (i.e., evaluations
of values clarification methods that did not use the term
values clarification).
Information Sources
We performed a systematic literature search in MED-
LINE, EMBASE, Web of Science, the Cochrane Library,
and CINAHL.
Search Strategy
We developed a draft search strategy in collaboration
with an information specialist (FB; see Acknowledg-
ments). Search strategies for each database are shown in
online Appendix 1. We reviewed search strategies with
all authors to ensure they were inclusive of relevant pre-
ference elicitation methods that might be used for values
clarification. We conducted hand searches by reviewing
articles that cited the previous version of these standards
(values clarification chapter) or a previous systematic
review of values clarification methods.
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Study Records: Data Management
We managed data with Covidence (Melbourne, Austra-
lia), reviewing data records at regular team meetings.
Study Records: Selection Process
Two independent reviewers (SC, MM, TP, CR, CR-B)
screened titles and abstracts to assess potential relevance,
with a third reviewer adjudicating discrepancies and dis-
cussions of questions and points of disagreement at regu-
lar team meetings. Two independent reviewers then
reviewed the full text of all articles deemed potentially
relevant based on their title and abstract. Discrepancies
in inclusion and exclusion at full text were adjudicated
through team discussions at regular meetings until we
reached consensus.
Study Records: Data Collection Process
Two independent, trained research team members (SC,
MM, TP, CR, CR-B) extracted data from each article
Table 2 Explicit Values Clarification Methods
Method Description
Adaptive conjoint analysis (example32) The user rates a series of sets of attributes and their levels, where choices
presented are tailored to earlier answers.
Allocation of points (example33) The user has a ‘‘budget’’ to ‘‘spend’’ on decision attributes, according to their
importance.
Analytical hierarchy process (example34) The user is asked to compare sets of options relative to predefined decision
criteria.
Best–worst scaling (example35) The user is asked to indicate the best and the worst object in repeated subsets of
a finite number of objects (case 1, also known as object scaling or MaxDiff),
the best and worst attributes within each of a number of profiles that
systematically vary across a multiple attributes and levels (case 2), or the best
and worst profiles from among 3 or more profiles (case 3).
Decision analysis or multicriteria decision
analysis (umbrella terma) (resource36,37)
The user is asked to directly indicate the extent to which a decision attribute or
outcome matters to them or how good or bad they deem it to be. These values
are then used in a model that calculates alignment between what matters to the
user and the available decision options.
Discrete-choice experiments (example38) The user is asked to make a series of choices between 2 (or more) alternatives,
where each alternative is characterized by attributes and their associated levels.
Open discussion (example39) The user discusses what matters to them in an unstructured or semistructured
discussion, possibly aided by a preset or user-created list of topics.
Pros and cons (resource40) The user lists advantages (pros) and disadvantages (cons) of options and/or
indicates the relevance (‘‘this matters to me’’) or importance (e.g., on a Likert
scale) of each advantage or disadvantage.
Ranking (example41) The user is asked to place attributes in order of importance, relative to each
other.
Rating scales (example42) The user indicates the importance of an attribute on a visual analog scale (e.g.,
paper-based visual analog scale, online slider) or Likert scale approximating a
visual analog scale. If the rating is then used to calculate and show which
option fits best, the method is classified as (multicriteria) decision analysis.
Social matching (example43) The user ‘‘observes different characters’ decisions and/or decision-making
processes and identifies 1 or more characters’’ with whom they identify.16
Standard gamble (example44) The user indicates their choice between a) living the rest of their life in a
particular health state (in the current context, a health state relevant to the
health decision they are making) and b) taking a gamble between 2 possible
outcomes: the probability p of living the remainder of their life in a state of
optimal health and the probability 1 –p of immediate death.
Time tradeoff (example44) The user indicates how many remaining lifetime years in full health they would
be willing to give up (i.e., ‘‘trade off’’) to avoid living for the rest of their life in
the health state representing the decision making option of interest.
aMulticriteria decision analysis or decision analysis is an umbrella term. It encompasses some of the other, more specific categories (e.g., discrete-
choice experiments, best–worst scaling.) When applicable, we use the more specific, narrower categories. Otherwise, we use the umbrella term
multicriteria decision analysis or, for brevity in figures, decision analysis. In addition, although within multicriteria decision analysis, the user may
be asked to rate attributes on rating scales, what distinguishes multicriteria decision analysis from other methods such as rating scales is that the
model calculates how well or poorly the options align with what matters to a user.
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using a standardized and pilot-tested data extraction
form based on a previous form17 and adapted to this
review. We resolved disagreements through discussion
until consensus was reached. We contacted authors to
collect any needed data that they did not report or were
unable to report in their publication.
Data Items
Regarding study participants, we recorded the sample
size for control and intervention groups along with basic
inclusion and exclusion criteria and whether or not they
were making the actual decision or if the study was
hypothetical. We defined a hypothetical scenario as one
in which people are asked (explicitly or implicitly) to
imagine that they are in a certain situation or facing a
certain decision. We defined a real scenario as one in
which people are facing a decision (e.g., because they
have received a diagnosis) or are members of a popula-
tion likely to face the decision in the near term (e.g., par-
ents of children eligible to receive vaccines within the
coming months).
Regarding interventions, we recorded the type of
explicit values clarification method as listed in Table 2.
We also recorded specific characteristics of each values
clarification method, namely, whether it explicitly
requires the user to engage with tradeoffs, whether it
explicitly shows the user the correspondence between
their options and what they value, and which, if any, the-
oretical or conceptual framework underpins it. Where
relevant, we recorded whether a variable was collected
via self-report, meaning whether responses were com-
pleted by participants themselves or by independent
researchers based on direct observation, including coded
qualitative data.
For comparators (controls), we recorded whether the
comparator was no values clarification method or an
implicit method and treated both as equivalent controls.
The Cochrane review of patient decision aids specifies
that all patient decision aids must contain implicit values
clarification methods at minimum,14 and it is accordingly
rare to have patient decision aids that do not present
potential benefits and harms of options in organized
ways. In other words, in the context of patient decision
aids, there is no meaningful distinction between implicit
methods and no values clarification. The different termi-
nology is simply a function of how authors choose to
name their control. We also recorded studies that com-
pared different types of explicit values clarification meth-
ods to each other.
Outcomes
Whenever such data were available, we extracted data
regarding values congruence (i.e., the extent to which
choices aligned with stated values) as our primary out-
come, as well as secondary outcomes: decision readiness
(worry, decision uncertainty, decision making prepara-
tion, knowledge), decisional conflict (measured with a
version of the Decisional Conflict Scale and/or its sub-
scales46), decision made, and postdecision and postimple-
mentation health and well-being (decisional regret,
longer-term health outcomes). Following data extraction
by pairs of trained reviewers (SC, MM, TP, CR, CR-B),
3 authors (HOW, SCD, JJ) mapped all outcomes into
broad outcome groups: worry (including perceived risk),
decision uncertainty (not including decisional conflict),
decisional conflict (decisional conflict scale or any sub-
scales), decision making preparation (including self-
efficacy for decision making), beliefs (including beliefs
about the condition or underlying decision structure),
knowledge, values (including reported utilities), shared
decision making (i.e., the extent to which shared decision
making occurred or not), effects on communication
(including quality, length, or existence of communica-
tion), satisfaction with care, preferences (i.e., preferences
expressed), decision (choice made and implemented) or
decisional intent (choice intended or made and not yet
implemented), values congruence, informed decision
making (i.e., the extent to which someone made an
evidence-informed, values-congruent, behaviorally
implemented decision9,47), postdecision feelings (includ-
ing satisfaction, regret), postdecision health, and user
assessment of the intervention (including acceptability,
satisfaction, perceived balance). We conducted meta-
analyses on primary outcome values congruence and sec-
ondary outcome decisional conflict, as these outcomes
had sufficient studies to do so.
Risk of Bias in Individual Studies
Independent, trained research team members assessed
risk of bias for each study using methods as defined in
the Cochrane handbook, section 8.5.48 We conducted
quantitative data syntheses with and without studies
identified as being at high risk of bias to determine the
sensitivity of overall findings to these studies.
Data Synthesis
We synthesized frequency-based results (e.g., how many
values clarification methods reflect a given design)
descriptively. To synthesize effects on outcomes, we
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pooled all experiments that evaluated a values clarifica-
tion method against no values clarification method or an
implicit method. For multiarmed studies in which the
comparison of a decision aid with and without a values
clarification method included an arm that was not rele-
vant to our comparison of interest (e.g., an information
booklet serving as a control condition in an evaluation
of the decision aid), we ignored the third arm. For
multiarmed studies containing 2 or more different values
clarification methods and 1 arm of implicit values clarifi-
cation or control, we considered each comparison of a
values clarification method against implicit values clarifi-
cation, meaning that each of the multiarmed studies
included in this review contributed multiple comparisons
to the pooled set.
To meta-analyze results for values congruence, we
pooled results from 11 studies using risk differences and
applying a random-effects model. Here, risk differences
refers to differences between treatment and control arms
regarding the risk of making a value-incongruent deci-
sion. We extracted dichotomous data indicating the fre-
quency (i.e., number of events and sample size) of values-
incongruent decisions. To meta-analyze results for deci-
sional conflict, we pooled results using standardized
mean differences applying a random-effects model. We
extracted data on total scores on the Decisional Conflict
Scale. We explored and reported consistency using Hig-
gins I2, which offers a measure of statistical heterogeneity
across pooled studies. Specifically, this statistic describes
the percentage of total variation across studies that is due
to heterogeneity rather than chance.49 When we included
multiple comparisons from a single study in a meta-
analysis, we conducted sensitivity analyses by restricting
meta-analyses to 1 comparison per contributing study
and meta-analyzing all possible combinations using a
random-effects model. This allowed us to ascertain
whether the overall Higgins I2 estimate might be influ-
enced by the inclusion of multiple study arms from simi-
lar populations. We used the Cochrane risk-of-bias tool
to assess study bias along 7 domains as well as to assess
an overall risk of bias. Where data permitted, we con-
ducted subgroup meta-analyses of different types of
explicit values clarification methods and of explicit values
clarification methods that do and do not contain specific
design features already identified in previous work,16
namely, whether the method explicitly requires the user
to engage with tradeoffs in any way, whether it explicitly
provides the user with the implications of what they
value, and which, if any, theoretical or conceptual frame-
work underpins it. We used P = 0.05 as a threshold for




Out of 30,648 records screened at the title and abstract
stage and 279 screened at the full-text stage, we identified
33 articles that met our inclusion criteria describing trials
of 43 values clarification methods. Twenty-four of the
articles were new articles identified in this update of the
International Patient Decision Aids Standards (IPDAS).
We excluded 2 of the articles previously included in the
IPDAS values clarification chapter because they did not
meet our revised inclusion criteria requiring randomized
controlled trials and instead reported, for example, pre–
post study designs. The PRISMA diagram of included
articles is shown in Figure 1.
The decision context varied across studies. Out of the
43 included trials, 25 (58%) addressed treatment deci-
sions, 9 (21%) screening decisions, 4 (9%) prevention,
3 (7%) genetic testing, and 2 (5%) diagnostic testing.








































No values clarification 
method (n = 75)
Values clarification method 
not tested independently (n 
= 66)
No paper available (n = 47)
Protocol only (n = 18)
Did not address a personal 
health decision (n = 14)
Values clarification method 
not tested at all (n = 11)
Review or meta-analysis (n 
= 5)
Duplicate not caught earlier
(n = 5)
Not a randomized 
experiment or trial (n = 4)
Retracted (n = 1)
Studies included in 
qualitave synthesis
(n = 33)
Figure 1 Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) diagram.
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Thirteen of the 43 trials (30%) centered on a yes/no deci-
sion to take an option or not, 18 (42%) a choice between
2 or more options, and 12 (28%) both a yes/no and a
choice between 2 or more options. Most decisions (22/43,
51%) were real decisions, meaning that the person was
making this decision in their actual life. The rest were
hypothetical (18/43, 42%), or it was not entirely clear
whether the decision was real or hypothetical (3/43, 3%).
The most commonly reported outcomes were decisional
conflict and/or its subscales (29/43, 67%), decision and/
or decisional intentions (22/43, 51%), knowledge (13/43,
30%), and values congruence (12/43, 28%).
As shown in the overview of included studies in Table
3, there was substantial diversity in the types of values
clarification methods used. Decision analysis or multicri-
teria decision analysis was the most commonly trialed
method. Full study details are available in online Appen-
dix 2.
Quality Assessment
Overall study quality was acceptable, with the majority
of studies at low risk of bias on most elements. Eight
studies were deemed to be at high risk of bias on 1 ele-
ment, with the majority in Blinding of Participants and
Personnel (Performance Bias). Eighteen additional stud-
ies were deemed unclear on this element. Blinding of
Outcome Assessment (Detection Bias) was the next most
common source of potential bias, with 1 study at high
risk of bias and 20 more unclear. Full details of risk of
bias assessments are available in online Appendix 3.
Values Congruence
As shown in Figure 2a, included explicit values clarifica-
tion methods, as a group, increased values congruence,
meaning people making decisions that aligned with their
stated values. Eleven out of 43 trials (26%) reported the
number of people who made values-congruent or values-
incongruent decisions. The pooled risk difference of mak-
ing a values-incongruent decision when using one of the
trialed values clarification methods was –0.04 (95% con-
fidence interval [CI], –0.06 to –0.02; P \ 0.001). The I2
of 28% indicates a low level of statistical heterogeneity.82
This estimate was robust to the inclusion and exclusion
of multiple comparisons from a single study (see online
Appendix 3, Suppl. Figures S10–S20).
Figure 2b shows a statistically significant subgroup
difference by type of values clarification method. The
results suggest that decision analysis is more likely to
encourage values-congruent decisions compared to other
explicit values clarification methods within this set of
trials (x2 = 9.25, P = 0.01). The results show no signifi-
cant subgroup differences by whether the method expli-
citly requires the user to engage with tradeoffs in any
way, whether it explicitly provides the user with the
implications of what they value, or whether the method
is underpinned by a formal theoretical or conceptual
framework (see online Appendix 3). There were no stud-
ies in this analysis with a high risk of bias.
Decisional Conflict
As shown in Figure 3a, explicit values clarification meth-
ods decrease decisional conflict. For the 14 of 43 (33%)
trials for which we had complete data, the pooled stan-
dardized mean difference for decisional conflict was –
0.20 (95% CI, –0.29 to –0.11; P\ 0.001). The I2 of 67%
represents moderate to high statistical heterogeneity. This
estimate was similar with inclusion and exclusion of mul-
tiple comparisons from a single study (see online Appen-
dix 3, Suppl. Figures S22–S26). Figure 3b shows there
was no significant subgroup difference by type of values
clarification method (x2 = 6.08, P = 0.05). We found no
significant subgroup differences by tradeoffs, implica-
tions, theory, or risk of bias (see online Appendix 3).
Head-to-Head Evaluations of Values Clarification
Methods
The 5 studies that compared values clarification methods
to each other reported findings that align with the find-
ings of our meta-analyses. Methods that provided users
with explicit feedback regarding how the decision options
align with their stated values led to somewhat better out-
comes, including greater values congruence.55 When
asked to compare methods to each other, study partici-
pants also preferred a values clarification method that
explicitly showed them how the decision options align
with their stated values.79 Different values clarification
methods yielded different patterns of attribute impor-
tance.66–68 Brief summaries of each study are available in
online Appendix 3.
Discussion
Overall, our systematic review and meta-analyses con-
firm that explicit values clarification methods improve
decision outcomes, notably by increasing values congru-
ence and decreasing decisional conflict. Patient decision
aids should include an explicit values clarification
method.
While the best explicit values clarification method
may depend on context—for example, urgent v. routine
(text continues on p. 816)
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Table 3 Study Details
Type(s) of Values
Clarification Method(s) Study Populationa Decision Summary of Findingsb
Adaptive conjoint
analysis
de Achaval et al., 201250 n = 208 people with knee
osteoarthritis
Whether to receive medication
and therapy or total knee
arthroplasty
Values clarification method decreased




Fraenkel et al., 200751 n = 87, age at least 60 years
old, self-report of pain
involving 1 or both knees on
most days of the month
Choice between 5 treatments
for knee pain
Values clarification method increased
self-confidence in and preparation for




Hess et al., 201552 n = 374 women aged 18 years
or older with abnormal
uterine bleeding and
potential candidates for
either surgical or medical
treatment
Whether or not to be treated
for abnormal uterine
bleeding and, if yes, which
treatment to undertake
Values clarification method did not




Hutyra et al., 201953 n = 200 people between 18
and 35 years of age at risk





Values clarification method increased





Jayadevappa et al., 201554 n = 743 people with newly
diagnosed localized prostate
cancer
Choice between 6 options for
early stage prostate cancer
Values clarification method improved
satisfaction with care, satisfaction with
decision, reduced regrets, and aligned
treatment choice with risk category.
Allocation of points Witteman et al., 202055 n = 817 adults asked to
imagine they had been
diagnosed with colon cancer
Choice between 2 hypothetical
surgeries for colon cancer
Values clarification method (strategy 6b
in article) increased values congruence
and reduced decisional conflict.
Analytical hierarchy
process
Myers, 200356 n = 199 men aged 50–69 years
with no personal history of
prostate cancer/benign
prostate hyperplasia
Whether or not to be screened
for prostate cancer
Values clarification method decreased
rates of prostate cancer screening.
Race/ethnicity analyses showed
African American men increased




Myers et al., 200557 n = 242 African American
men, 40–69 years of age and
no history of prostate cancer
Whether or not to be screened
for prostate cancer and, if
yes, choice of method/extent
of screening
Values clarification method increased
prostate cancer screening.
Best–worst scaling Shirk et al., 201758 n = 122 men with incident
localized prostate cancer
Choice between 3 options for
incident localized prostate
cancer
Values clarification method decreased
decisional conflict.




Whether or not to have a
prenatal diagnosis for Down
syndrome
Values clarification method helped
women make more informed prenatal
diagnosis decisions.
Decision analysisc Clancy et al., 198860 n = 1,280 resident and faculty
physicians unvaccinated
against hepatitis B
Choice between 3 options to
manage risk of hepatitis B
Values clarification method resulted in








Clarification Method(s) Study Populationa Decision Summary of Findingsb
Decision analysisc Feldman-Stewart
et al., 201261
n = 156 people with newly
diagnosed prostate cancer
Choice between more than 5
main options for early stage
prostate cancer
Values clarification method increased
preparation for decision making and
decreased decision regret. Decisional
conflict decreased with and without
values clarification method.
Decision analysisc Hopkin et al., 201962 n = 349 adults asked to
imagine that they had to
choose a statin
Choice between 5 commonly
used statins
Values clarification method reduced
decisional conflict and increased levels
of preparation for decision making.
Decision analysisc Montgomery et al., 200363 n = 217 adults aged 30–80
years with newly diagnosed
hypertension
Whether or not to start drug
therapy for hypertension
Values clarification method increased
knowledge and reduced total decisional
conflict by significantly reducing
scores on uninformed, unclear values
and unsupported subscales and
somewhat reducing scores on
uncertainty subscale. Values
clarification method did not influence
scores on decision quality subscale, nor
did it change state anxiety, decision
intention, or ultimate decision.
Decision analysisc Montgomery et al., 200764 n = 742 pregnant women with
1 previous lower-segment
caesarean section
Choice of planned mode of
delivery
Values clarification method reduced
decisional conflict and increased
frequency of having a vaginal birth.
Decision analysisc Witteman et al., 201565 n = 407 parents who make
medical decisions for at least
1 child aged 6 months to 18
years and whose child had
not yet received the flu
vaccine
Whether their child would
receive a vaccine against
influenza this flu season
Values clarification method had no
effect on values congruence. Values
clarification method combined with
best practices in risk communication
increased intentions to vaccinate,
particularly among participants who
had not had their children vaccinated
against influenza in the past 5 years.
Decision analysisc Witteman et al., 202055,d n = 1,731 adults asked to
imagine they had been
diagnosed with colon cancer
deciding between 2 treatment
options
Choice between 2 hypothetical
surgeries for colon cancer
Values clarification method (strategies
2a, 2a + 2b, 6c, 6b + 6c in article)
increased values congruence and
reduced decisional conflict when this




Brenner et al., 201466 n = 615 people between the
ages of 50 and 75 years at
average risk for colorectal
cancer
Whether or not to be screened
for colorectal cancer, and, if
yes, which screening test to
use
Values clarification method influenced
choice of most important screening test
attribute but did not affect unlabeled








Clarification Method(s) Study Populationa Decision Summary of Findingsb
Discrete choice
experiment
Pignone et al., 201267 n = 104 adults aged 48–75
years at average risk for
colon cancer
Whether or not to be screened
for colorectal cancer and, if
yes, which screening test to
use
Values clarification method influenced
choice of most important attribute but
did not affect values clarity, intent to




Pignone et al., 201368 n = 604 men aged 50–70 years
at average risk of prostate
cancer
Whether or not to be screened
for prostate cancer
Values clarification method slightly
reduced choice of dying as the most
important attribute and increased
unlabeled PSA-like screening option
but did not influence intent to be
screened.
Open discussion Au et al., 201269 n = 306 people with chronic
obstructive pulmonary
disease
Preferences for end-of-life care Values clarification method helped
identify what mattered to patients
regarding end-of-life care and
communication. Quality of
communication improved.
Open discussion Epstein et al., 201870 n = 99 people with advanced
gastrointestinal cancer
Choice between options for
end-of-life care
Values clarification method improved
communication about future medical
cancer care but had no effect on
decisional conflict or well-being and
increased distress.




Values clarification method resulted in
minimal improvements in self-reported
health status, lower use of a more
invasive treatment, higher patient
satisfaction, more frequent clinician
perceptions of ‘‘longer than usual’’
consultations, and lower overall costs.
Providing information alone did not
affect treatment choices.
Open discussion Lerman et al., 199772 n = 700 women aged 18–75
years who had had at least 1
first-degree relative with
breast and/or ovarian cancer
Whether or not to provide a
blood sample for BRCA1
testing in the future
Values clarification method increased
the perceived importance of the
limitations and risk of BRCA1 testing
and decreased the perceived
importance of the benefits of BRCA1
testing. No effect of values
clarification method on intent to test.
Open discussion Matheis-Kraft et al., 199773 n = 60 women over age 70
years with at least 1 family
member or friend who might
act as their proxy to make
decisions about life-
sustaining treatment
Preferences for care in case of
decisional incapacity
Values clarification of method’s
effectiveness or lack thereof depended
on which statistic (k or percent
agreement) was used to measure








Clarification Method(s) Study Populationa Decision Summary of Findingsb
Pros and cons Abhyankar et al., 201074 n = 30 healthy women asked
to imagine having been
diagnosed with breast
cancer, undergoing





chemotherapy or taking part
in a clinical trial testing a
new chemotherapy for early
stage breast cancer
Values clarification method resulted in
more use of personal values when
evaluating attributes of options,
somewhat less ambivalence, and less
uncertainty and did not change
preferred option.
Pros and cons O’Connor et al., 199975 n = 201 women aged 50–69
years who had never used
hormone therapy
Whether or not to take
hormone replacement
therapy after menopause
Values clarification method had no
effect on clarity of values, values
congruence, total decisional conflict,
other subscales of the Decisional
Conflict Scale, or acceptability of
intervention.
Pros and cons Paquin et al., 202176 n = 1,000 people aged 18–44
years who were pregnant or
whose partner was pregnant
or planning to become
pregnant in the next 2 years
Whether or not to use
genomic sequencing to
identify genetic variants in
one’s child
Values clarification method decreased
parental beliefs against genomic
sequencing.
Pros and cons Peinado et al., 202015 n = 1,000 people aged 18–44
years who were pregnant or
whose partner was pregnant
or planning to become
pregnant in the next 2 years
Whether or not to enroll their
newborn child in a medical
research study that would
involve screening for genetic
conditions
Values clarification method decreased
decisional regret and increased clarity
of personal values but had no effect on
overall decisional conflict or on intent
to have one’s child tested.
Pros and cons Witteman et al., 202055 n = 772 adults asked to
imagine they had been
diagnosed with colon cancer
Choice between 2 hypothetical
surgeries for colon cancer
Values clarification method (strategy 4b
in article) reduced decisional conflict
but did not change values congruence.
Rating scales Garvelink et al., 201477,d n = 271 healthy women Whether or not to undergo
fertility-preserving
procedures prior to cancer
treatment
Values clarification method had no
effect on knowledge or decisional
conflict.
Rating scales Kuppermann et al., 201478 n = 710 pregnant women who
had not yet undergone
screening or diagnostic
testing for fetal aneuploidy
in the current pregnancy
Whether or not to have any
screening or diagnostic
testing for fetal aneuploidy;
if screening or testing is
desired, whether to start with
screening or with invasive
diagnostic testing; and which
specific screening and/or
diagnostic test(s) to undergo
Values clarification method increased
patient knowledge and resulted in less
invasive prenatal test use and more
informed choices. Values clarification
method did not change decisional
conflict or decisional regret.
Rating scales (with and
without decision-
analytic summary)
Feldman-Stewart et al., 200679 n = 90 male volunteers asked
to imagine that they had just
been diagnosed with early
stage prostate cancer
Choice between 4 options for
early stage prostate cancer
Participants preferred values
clarification method with decision-
analytic summary over values
clarification method without summary







Clarification Method(s) Study Populationa Decision Summary of Findingsb
Rating scales Witteman et al., 202055 n = 785 adults asked to
imagine they had been
diagnosed with colon cancer
Choice between 2 hypothetical
surgeries for colon cancer
Values clarification method (strategy 6a
in article) reduced decisional conflict
but did not change values congruence.
Rating scales + ranking Brenner et al., 201466 n = 614 people between the
ages of 50 and 75 years at
average risk for colorectal
cancer
Whether or not to be screened
for colorectal cancer, and, if
yes, what screening test to
use
Values clarification method increased
the importance placed on risk
reduction as an important attribute but
did not affect unlabeled test preference,
values clarity, or intent to be screened.
Rating scales + ranking Pignone et al., 201267 n = 104 adults aged 48–75
years at average risk for
colon cancer
Whether or not to be screened
for colorectal cancer, and, if
yes, what screening test to
use
Values clarification method influenced
choice of most important attribute but
did not affect values clarity, intent to
be screened, or choice of screening test.
Rating scales + ranking Pignone et al., 201368 n = 609 men aged 50–70 years
at average risk of prostate
cancer
Whether or not to be screened
for prostate cancer
Values clarification method increased
the importance of dying (attribute
importance) but did not influence
intent to be screened.
Rating scales + ranking Sheridan et al., 201080 n = 137 men aged 45–80 years
with no history of
cardiovascular disease
Whether or not to initiate
behaviors to prevent
coronary heart disease and,
if so, which behaviors
Values clarification method had no
effect. Decisional conflict, perceived
values congruence, and self-efficacy for
health behaviors improved with and
without values clarification.
Behavioral intentions did not change.
Time tradeoff + rating
scales
Frosch et al., 200881 n = 611 men older than 50
years
Whether or not to be screened
for prostate cancer
Values clarification method increased
cancer knowledge scores and decreased
decisional conflict.
PSA, prostate-specific antigen.
an is given for the study as a whole. See supplementary appendix for further details about each study.
bOutcomes are in bold.
cDecision analysis or multicriteria decision analysis is an umbrella term. It encompasses some of the other, more specific categories (e.g., discrete-choice experiments, best–worst
scaling). Throughout the article, when applicable, we use the more specific, narrower categories. Otherwise, we use the umbrella term multicriteria decision analysis or, for brevity in
figures, decision analysis.





Figure 2 (a) Risk of values-incongruent decisions: overall (all values clarification methods together). (b) Risk of values-
incongruent decisions by type of values clarification method.
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care or the extent to which a decision has a clear set of
decision attributes—our analyses suggest that patient
decision aid developers may wish to consider methods
that draw on multicriteria decision analysis. The apparent
advantages of such methods shown in our analyses may
reflect similarities between the process and the outcome.
In other words, increased values congruence yielded by
decision-analytic methods may be a function of the ways
Figure 3 (a) Decisional conflict: overall measure. (b) Decisional conflict by type of values clarification method.
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in which such methods transparently show people how
their options align with their stated values. We also cau-
tion that when these methods use prespecified attributes,
there might not be the flexibility for users to add new
attributes, highlighting the importance of research to
inform attribute selection. We acknowledge that some
researchers have argued that health professionals having
an unhurried, high-quality conversation with patients
may be a preferred approach for at least some patients,
especially when decision attributes are many and varied.
However, in this systematic review, trials of Open Discus-
sion values clarification methods did not demonstrate
strong results, suggesting that such an ideal may be diffi-
cult to achieve.
To advance further knowledge on the merits and pit-
falls of different values clarification methods, we recom-
mend that authors of future trials of values clarification
methods report 4 outcomes: decisional conflict, decision
or decision intention, values congruence, and decisional
regret. When possible, authors should make use of vali-
dated scales that have good psychometric properties and
are commonly reported, as this facilitates evidence
synthesis.
Decisional conflict should be assessed before people
make the decision, using a version of the Decisional Con-
flict Scale.46,83 Decisions or decision intentions should be
assessed when the decision is made.
Values congruence should be assessed once the deci-
sion is made. We acknowledge that including values con-
gruence as an outcome brings both measurement and
conceptual issues. Measurement issues exist because
there are disagreements about how to measure what mat-
ters to people (or, indeed, whether it is conceptually pos-
sible to do so) and compare such measures to what
people choose.84 Values congruence should not be mea-
sured using the values clarity subscale of the Decisional
Conflict Scale, as this subscale measures perceived values
clarity, not values congruence.55 Further research is
required to determine whether measuring values congru-
ence might introduce bias or otherwise negatively influ-
ence decision making.
Decisional regret should be assessed with a version of
the Decisional Regret Scale85,86 after people make the
decision, ideally with a sufficiently long delay so that
longer-term effects can be captured. This scale, whose
items include, ‘‘I would go for the same choice if I had to
do it over again,’’ assesses how people feel about the deci-
sion itself, not the decision process. An included study in
this review showed that a values clarification method
reduced decisional regret but only after a year had passed
following implementation of the decision.61
For all 4 measures, authors should clearly report sam-
ple mean and sample standard deviation for continuous
measures, numbers in each category for categorical mea-
sures, and sample size per study arm in all cases. Finally,
we recommend that patient decision aid developers
explain the rationale for their choice of values clarifica-
tion method.
Our study has 4 main limitations. First, the included
data were of moderate quality. Although this review
includes many robust trials, the included studies often
measured different outcomes or the same outcomes in
different ways, there were missing data in some studies,
some studies had high risk of bias (often because it was
not possible to prevent study participants from ascertain-
ing the study arm to which they were assigned), and
some of our meta-analyses had high heterogeneity.
Together, these issues suggest a degree of caution in our
conclusions. Second, we did not distinguish between sub-
types of values clarification methods. For example, dif-
ferent adaptive conjoint analysis exercises may be very
different from each other, as might open discussions or
many other values clarification methods we grouped
together, particularly those we grouped under the broad
umbrella term of multicriteria decision analysis. Indeed,
the values clarification methods used and trialed may
simply reflect authors’ interests and expertise. The selec-
tion may also reflect views about whether it is preferable
to invite users to explicitly consider individual attributes
(e.g., rating scales or multicriteria decision analysis) or to
consider options more holistically (e.g., discrete-choice
experiments or adaptive conjoint analysis). Given the
breadth of methods available, further comparative effec-
tiveness research is needed to conclusively determine the
superiority of any given method. Third, although assess-
ment of values generally occurred following provision of
information about options and attributes, we were
unable to determine whether all instances of improved
values congruence reflected informed values, as not all
trials measured knowledge. Fourth and finally, our pri-
mary findings were heavily influenced by studies con-
ducted with relatively homogeneous populations making
hypothetical decisions. Although our sensitivity analyses
suggested no differences between studies in real and
hypothetical contexts, we nonetheless believe further
study is needed in more diverse populations making real
decisions before drawing firmer conclusions.
Our study also has 3 main strengths. First, we catalog
definitions and resources regarding values clarification
methods, as well as recommended outcomes to report in
studies. In doing so, we hope to offer more clarity and
structure to a literature that can be confusing to
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navigate, particularly for those who are newer to devel-
oping patient decision aids. Second, we begin to answer
a core question that commonly arises when developing a
patient decision aid: when including a values clarification
method, which type of method should one use? Third
and finally, we used rigorous methods and an expansive,
systematic search. By conducting a systematic review, we
reduced our likelihood of missing relevant studies. By
including meta-analyses, we offer stronger findings and
recommendations than would be possible without pool-
ing data across multiple studies.
In conclusion, particularly in contexts in which people
may make health decisions unaligned with what matters to
them, patient decision aids should include an explicit val-
ues clarification method. Patient decision aid developers
may wish to consider the potential advantages of multicri-
teria decision analysis. Future research should further
investigate which methods lead to the best outcomes across
or within particular decisions, populations, and settings.
Authors of randomized controlled trials of explicit values
clarification methods should report decisional conflict,
decision made, values congruence, and decisional regret.
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